Description: Vertex Pharmaceuticals has underperformed the broader Nasdaq index over the past year. However, Wall Street analysts remain moderately optimistic about its prospects.

Description: Vertex Pharmaceuticals recently reported positive clinical trial data for povetacicept in IgA nephropathy and primary membranous nephropathy, showing significant proteinuria reduction and stabilization of kidney function, and announced plans to begin rolling regulatory submissions for potential FDA accelerated approval in 2025. This breakthrough reinforces Vertex’s research capabilities in advancing therapies for kidney diseases, drawing strong interest from hedge funds and analysts alike as...

Description: Vertex delivered strong performance across the board in Q3 with $3.08 billion in revenue, reflecting double-digit growth versus Q3 2024. As we continue to extend our leadership in CF, we're also diversifying our revenue base by product and by geography with the growing global momentum of CASGEVY and the broad uptake JOURNAVX and acute pain across a wide range of prescribers pain types and settings of care, Concurrently, we are forward planning for the fourth vertical of Vertex's growth. Two, bring forward a medicine that restores CFTR function to normal levels as measured by sweat chloride and to do so from as early in life as possible.

Description: If you have ever wondered whether Vertex Pharmaceuticals is a bargain right now, you are not alone. Let's break down whether the current price really stacks up to the company's fundamentals. Despite some volatility over the past year with a -7.0% return, Vertex has still delivered a solid 90.6% gain for investors over the last five years and is currently up 6.5% in 2024. Recently, Vertex Pharmaceuticals has grabbed attention with new product launches, advances in its pipeline, and positive...

Description: Prediction: Vertex will be much larger by the end of the decade.

Description: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best large cap stocks to invest in for the long term. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was initiated with an Outperform rating by Scotiabank on November 12 with a $495 price target. The same day, Evercore ISI reiterated a Buy rating on the stock. However, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) […]

Description: Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 2.7% in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.

Description: BOSTON, November 19, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi’s 2025 Global Healthcare Conference. Charlie Wagner, Chief Operating and Financial Officer, and David Altshuler, Chief Scientific Officer, will participate in a fireside chat on Wednesday, December 3, 2025, at 9:00 a.m. ET.

Description: Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

Description: Vertex Pharmaceuticals (VRTX) has drawn attention with new data from its RUBY-3 trial, showing that povetacicept has achieved meaningful results in two kidney diseases. The recent FDA designations further highlight ongoing momentum in its late-stage pipeline. See our latest analysis for Vertex Pharmaceuticals. The latest pivotal trial results and fresh FDA recognition appear to have injected new optimism into Vertex Pharmaceuticals, with the stock posting an impressive 11% share price return...

Description: Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: Vertex Pharmaceuticals’ stock has trailed behind the broader market, but analysts are still taking a moderately bullish stance about its prospects.

Description: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, Stifel maintained a Hold rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The firm also kept its price target at $445 for the stock. Stifel’s analysts referenced Vertex’s presentation of povetacicept (a dual BAFF/APRIL inhibitor) open-label Phase […]

Description: It's a good idea to go against the current market sentiment on this one.

Description: These stocks stand above the rest.

Description: Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Description: Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria reductions and eGFR stabilization with povetacicept in patients with IgA nephropathy and primary membranous nephropathy, alongside a favorable safety profile and regulatory designations from the FDA. This positions Vertex as the only company advancing a dual BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases, highlighting its growing presence in...

Description: -Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine- -CASGEVY® momentum accelerating; nearly 300 patients have been referred to Authorized Treatment Centers (ATCs), approximately 165 patients have completed their first cell collection and 39 have received infusions across all regions; Vertex expects clear line of sight to over $100 million in to

Description: Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively as margin compression and operational investments weighed on sentiment. Management attributed top-line gains primarily to the ongoing expansion of its cystic fibrosis (CF) franchise and early strength from new launches in acute pain and genetic therapies. CEO Reshma Kewalramani pointed to “strong response from patients and physicians” for ALYFTREK and highlighted momentum w

Description: BOSTON, November 08, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove is the o

Description: Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.

Description: Vertex Pharmaceuticals (VRTX) swung to profitability as the company left behind five years of annual earnings declines averaging 10.4%. Looking ahead, management projects earnings growth of 13.3% per year and revenue growth of 8.8%, both trailing the broader US market’s respective forecasts of 16% and 10.5%. With margins turning positive and a high quality of earnings now established, investors will be watching continued profit momentum. The share price of $421.67 remains well below an...

Description: Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older CF drug.

Description: VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.

Description: Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $11.95 billion at the midpoint. Its non-GAAP profit of $4.80 per share was 4.9% above analysts’ consensus estimates.

Description: University of Alberta-led research highlights emerging hydrogen storage potential at Robinsons River Salt DomeVANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that the University of Alberta has submitted an abstract titled “Structure Assessment of the Robinson River Salt Dome for Hydrogen Storage” to the Canadian Hydrogen Convention committee, in relation to an opportunity to

Description: While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.

Description: Vertex stock dipped late Monday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older cystic fibrosis treatment, Trikafta.

Description: Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $11.95 billion at the midpoint. Its non-GAAP profit of $4.80 per share was 4.9% above analysts’ consensus estimates.

Description: On a per-share basis, the Boston-based company said it had profit of $4.20. Earnings, adjusted for one-time gains and costs, were $4.80 per share. The results exceeded Wall Street expectations.

Description: BOSTON, November 03, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance.

Description: This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Monday. This is TheStreet’s Stock Market Today for Nov. 3, 2025. You can follow the latest updates on the market ...

Description: These healthcare stocks are making strides in very important ways.

Description: Following President Trump's return from Asia, eyes are on whether an end to the government shutdown is in sight. Meanwhile, investors will dig into earnings from McDonald’s, Palantir and a host of other companies.

Description: Vertex Pharmaceuticals (VRTX) is gaining attention as new clinical data for its kidney disease therapy, povetacicept, shows encouraging results. The company’s portfolio is also benefiting from steady cystic fibrosis sales and early momentum from its latest treatments. See our latest analysis for Vertex Pharmaceuticals. The excitement around Vertex’s kidney therapy news comes as share price momentum has started building again, with a 1-month share price return of 5.5% and year-to-date gains of...

Description: This stock isn't bulletproof. But it should be a big winner over the coming years.

Description: Vertex, Corteva, and many more will also report earnings. On the economic front, The Supreme Court will hear arguments on the legality of Trump’s tariffs, and ADP will release October employment data.

Description: Markets look set to enter the fifth full week of a US government shutdown as investors parse Powell's comments, news of a trade deal between Washington and Beijing, and another mammoth week of earnings.

Description: Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know.

Description: Market Domination Overtime host Josh Lipton previews several of the biggest stories to come throughout next week, including: — The nearing expiration of SNAP benefits funding (Supplemental Nutrition Assistance Program) as a federal judge orders the Trump administration to continue funding the program. — Earnings results from Berkshire Hathaway (BRK-A, BRK-B) this Saturday and quarterly results from companies like Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Qualcomm (QCOM), and McDonald's (MCD) throughout the rest of the week — The beginning of open enrollment for health insurance coverage. — Economic commentary from a handful of Federal Reserve officials. — Tesla's (TSLA) shareholder meeting, where investors will vote on CEO Elon Musk's $1 trillion executive pay package. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: RIGL's rising Tavalisse sales, along with incremental sales from Rezlidhia and Gavreto, could power another earnings beat in the quarter to be reported.

Description: The growth for Vertex’s Journavax painkiller is just beginning to ramp up, given the potential size of the nonaddictive drug market.

Description: In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $417.21, denoting a -1.23% move from the preceding trading day.

Description: Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.

Description: Get a deeper insight into the potential performance of Vertex (VRTX) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Description: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on October 21, setting a price target of $478. The analyst based the optimistic rating on the positive potential of the company’s kidney franchise, stating that its […]

Description: Thinking about what to do with Vertex Pharmaceuticals stock? You are not alone. The biotech powerhouse has seen its shares oscillate lately, drawing more than a few glances from investors deciding whether to get in, stay in, or head for the exits. The last close landed at $420.17, with the stock posting an 8.9% gain over the past 30 days. This has been a solid rebound after a slower patch that saw shares down 1.4% this week and 10.7% over the past year. Looking further back, the story turns...

Description: Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.

Description: Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: These two have been neglected by Wall Street too much.

Description: BOSTON, October 27, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the UBS Global Healthcare Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, November 11, 2025, at 10:15 a.m. ET.

Description: The gene-editing biotech Intellia Therapeutics said Monday it had paused two trials of one of its lead experimental treatments after a patient was hospitalized due to liver problems. On an investor call, Intellia’s CEO, John Leonard, said that the company had learned Friday that a patient in a trial of the company’s experimental gene-editing treatment for a heart disease called ATTR-cardiomyopathy had been hospitalized after reporting stomach pain.

Description: Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Description: Vertex appears to be by far the better buy right now.

Description: Vertex Pharmaceuticals recently announced important updates on its investigational kidney disease therapy povetacicept, including FDA regulatory progress and upcoming data presentations, as well as new clinical data for its cystic fibrosis therapy ALYFTREK presented at a major medical conference. The only dual BAFF+APRIL inhibitor currently in pivotal trials for multiple kidney diseases, povetacicept strengthens Vertex's position in B cell-mediated disease innovation and broadens its...

Description: BOSTON, October 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company’s most recently approved medicine, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), at the North American Cystic Fibrosis Conference (NACFC) held from October 22-25 in Seattle, Washington.

Description: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best long term low volatility stocks to buy right now. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on October 21 with a price target of $563. The analyst based the optimistic rating on the company’s strong growth potential […]

Description: Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Description: These companies have a habit of beating the market, and they are far from having peaked.

Description: Vertex Pharmaceuticals (VRTX) shares have been fairly steady recently, as investors digest the company’s financial performance over the past month. The stock is up 8% since early May. This reflects a cautious optimism about ongoing growth in the biotech sector. See our latest analysis for Vertex Pharmaceuticals. While Vertex Pharmaceuticals’ 1-day and 1-week share price returns have been positive, it is the rebound since early May that stands out, hinting at growing investor confidence...

Description: The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $416.81, representing a +2.01% change from its previous close.

Description: BOSTON, October 17, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential

Description: Vertex is still growing fast but the market has given investors another chance to fill up on shares.